Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2005

View Archived Issues

Gabexate mesilate tested for therapeutic potential in gut hypoperfusion

MG-132 modulates cytokine response and mortality in preclinical sepsis model

Protective effects of green tea polyphenols against acetaminophen-induced liver damage

Novasome delivery of H2 antagonists shows promise for periodontal disease

Pharmacokinetics and tissue distribution of fumitremorgin C in tumor-bearing mice

Icos and Solvay to copromote AndroGel

Priority review for Tygacil NDA

YM Biosciences and Shin Poong Pharmaceutical partner for tesmilifene

Neose and BioGeneriX enter option agreement for GlycoPEGylation technology

Access updates recent developments

Lilly withdraws duloxetine NDA for stress urinary incontinence

Enrollment begins in phase II study of MS-I.E.T.

Northwest to begin phase III trial of DCVax-Prostate

New indications approved for Neoral and Sandimmun in Japan

Preclinical targeting of B-cell lymphoma using the humanized monoclonal antibody CMC-544

Aromatization reported to increase the cognitive benefits of testosterone supplementation

Phase II data on the benefits of Acclaim in chronic stable angina

Antirheumatic effects of MMP inhibitor in adjuvant-induced arthritis model

Chronic blockade of ETB receptors exacerbates degeneration of cardiomyocytes

Ajinomoto patents TRPV receptor ligands for treatment of pain

New compounds for immune-mediated diseases designed at Merck

OSI scientists develop new glycogen phosphorylase inhibitors

Integrin antagonists in early development at Genentech

Calcium channel blockers emerge from NeuroMed R&D

Guilford discloses new PARP inhibitors

RDP-58 active in model of interstitial cystitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...